Proceeding contribution from Lord Darzi of Denham (Labour) in the House of Lords on Wednesday, 12 December 2007. It occurred during Committee of the Whole House (HL) and Debate on bill on Human Fertilisation and Embryology Bill [HL].
Human Fertilisation and Embryology Bill [HL]
Although the provisions on access to information are not, perhaps, the most high-profile element of this Bill, they have attracted strong views from those in the fertility sector. Let me first address the two amendments tabled by the noble Lord, Lord Patel. The first, Amendment No. 64A, relates to disclosure of identifiable information held on the HFEA register with consent. The second, Amendment No. 64B, relates to disclosure of information without consent. During the public consultation on the Bill, the view was expressed that the additional level of protection applied to identifying information about treatments and other activities regulated by the 1990 Act was unnecessary, that it hindered the legitimate exchange of information and that the protection provided by the Data Protection Act 1998 and the common law on confidentiality, which regulate disclosure of information from most other health records, would provide sufficient safeguards for patients, gamete and embryo donors, and offspring. In my clinical practice, I am well used to working within these controls, so I can appreciate why that view is held. It is certainly shared by the noble Lord, whose amendments would relax the prohibition on disclosure of identifying information with, in the case of Amendment No. 64B, the practical effect of leaving identifying information essentially subject to the requirements of the Data Protection Act and the common law. However, in setting the level of protection for identifying information covered by the 1990 Act and this Bill, the Government are obliged to have regard to the requirements of a European Union directive that sets standards of quality and safety in relation to human tissues, including gametes and embryos, intended for human application. The Government are of the view that Article 14 of the directive, which sets the requirements on data protection and confidentiality for health records, requires statutory protection that goes further than that which the Data Protection Act and the common law provide. This is due to the fact that it involves the use of a person’s tissue for someone else. We consider that this level of protection is achieved by the prohibition on disclosure in new Section 33A. We have, however, added some new exceptions in new Section 33A that will ensure that disclosure for legitimate purposes, such as patient care or the investigation of a potential offence, is not inappropriately impeded. Moreover, the power in the 1990 Act to make regulations adding further exceptions to the prohibition is still included in the Bill, in new Section 33B. Therefore, if it becomes evident that there are further circumstances in which disclosure legitimately needs to be made, it will be possible to make regulations to allow for this. The noble Lord’s Amendment No. 64A would allow disclosure of identifying information with the consent of the persons to whom the information relates. However, it could also permit disclosure of information to those who were conceived using donated gametes or a donated embryo. The exceptions relating to donors and those born as a consequence of donation apply in a different way from those that relate to people who have received treatment services. In particular, identifying information about donors cannot be released to those conceived using their donation until the donor-conceived person reaches 18 and chooses to find out the donor’s identity. Separate provisions for donor information are necessary to prevent information being disclosed to a donor-conceived person outside the system provided for in the new sections inserted by Clause 24. The amendment could lead to a donor-conceived person, possibly a young teenager, obtaining identifying information about their donor outside the system provided for in new Section 31ZA. I imagine that that is not what the noble Lord was seeking. With regard to information about those who have received treatment services, the aim of the amendment is already achieved by the exception in new Section 33A(2)(h). This, together with the exceptions allowing wider disclosure by the HFEA, HFEA-licensed establishments and others to whom the prohibition in the 1990 Act applies, will allow the type of disclosure that the noble Lord seeks. New Section 33A strikes an appropriate balance between the obligation to protect the confidentiality of patients, children and donors, and ensuring that information can be disclosed where it is necessary. I turn to the amendment of the noble Earl, Lord Howe. A key recommendation of the 1984 Committee of Inquiry into Human Fertilisation and Embryology, chaired by the noble Baroness, Lady Warnock, was the creation of a register of assisted conception treatments that would allow the long-term health implications for children born as a result of those treatments to be monitored. Since August 1991, the HFEA register has kept a record of every IVF and donor insemination treatment cycle carried out by licensed clinics in the UK, including, where known, its outcome. The HFEA register represents one of the most comprehensive stores of information on these treatments in the world. For that reason the Government intend to ensure that the Bill will pave the way to enabling better use to be made of this valuable resource, to improve our knowledge about these treatments. We will remove the barrier in the 1990 Act that prevents patients giving their consent to the disclosure of identifying information from the HFEA register. Patients will have the opportunity and the choice, on their treatment consent form, to state clearly whether they would be agreeable to their information being disclosed for research purposes. However, this is a solution only for future treatments. We also need to find a way to ensure that the wealth of information collected over the past 17 years can also be used to benefit research. To ensure that this can happen, the Government propose the affirmative regulation-making power in new Section 33C, with a view to enabling researchers to request identifying information from the HFEA register, licensed clinics and providers of non-medical fertility services, where it is not reasonably practical to obtain the consent of the persons to whom the information relates. I assure the noble Earl that before such regulations are introduced, it is appropriate that a full consultation takes place. Following this, the proposed model for releasing the information for research will be included in regulations, which will be debated in both Houses. We intend that it will be possible to disclose identifying information under the regulations only where the research is necessary in the public interest, or, in the cases of medical research, in the interests of improving patient care. As the data on the HFEA register and records held in licensed clinics go back to 1991, it may no longer be practical to obtain consent to disclosure from persons to whom the information relates. Without the authorisation process, which this clause enables the Secretary of State to put in place, using regulation, it is likely that the data from a large number of records would be barred from use in research, thereby limiting the benefits that could be derived from this information. A practical outcome of such a restriction might be that researchers could not be given a complete set of data on patients who have undergone a specific type of fertility treatment, such as intracytoplasmic sperm injection, or ICSI, and so might not be able to assess fully whether this treatment has any link with the development of particular genetic conditions in some of the resulting children. Similarly, researchers hoping to link HFEA data with information held in other health registries, such as a local cancer registry, would not be able to have a complete data set, again limiting their ability to determine whether there is any indication of a link between a certain type of fertility treatment or process and the onset of a particular medical condition. Regulation-making power of the type proposed in new Section 33C is not new. A similar authorisation procedure already exists in England and Wales for the NHS or privately funded healthcare systems. A system where an application made to the Secretary of State for access to confidential patient information, without consent, was established under the regulations made under Section 251 of the National Health Service Act 2006. The patient information advisory group advises the Secretary of State on the appropriateness of approving applications for the disclosure of information under those regulations. Section 33C(2) includes powers to establish one or more bodies to consider applications for access to identifying information from the HFEA register and from health records held by licensed establishments. The process established by the regulations will need to work equally in all four home countries. The use of the existing PIAG system could be one option, at least in England and Wales. Clinical and scientific professionals have long regarded the audit of clinical practice and studies into the long-term results of medical treatments to be one of the most important parts of healthcare service and vital if we are properly to serve the interests of our patients and the wider public. Treatments such as IVF are widely considered to be safe for both patients and offspring, but I believe we would be failing those patients and children if we did not take every opportunity to ensure that long-term follow-up studies can take place to confirm that view. The authorisation process allowed for in this clause is intended to provide a method of last resort. It cannot be used by researchers to circumvent the need to seek patients’ consent, where it is reasonably practical to consult them. New Section 33C(5) sets the obligation that the regulations may not enable or require identifying information to be disclosed or processed for any purpose, if it would be reasonably practical to achieve the purpose by other means. I hope that will reassure the noble Lord and he will feel able to withdraw his amendment.
Secondary information
- Type
- Proceeding contribution
- Reference
- 697 c253-6
- Session
- 2007-08
- Chamber / Committee
- House of Lords chamber
- Subjects
- Disability Disclosure of information Data protection Civil partnerships Death Abortion Congenital abnormalities Fertility Human embryo experiments Donors Human Fertilisation and Embryology Authority Ethics IVF Fathers Parents Parental responsibility Registration of births, deaths, marriages and civil partnerships Research
- Legislation
- Human Fertilisation and Embryology Bill (HL) 2007-08
- Link
- View this Proceeding contribution on www.publications.parliament.uk
Librarians' tools
- Timestamp
- 2023-12-16 01:17:51 +0000
- URI
- http://data.parliament.uk/pimsdata/hansard/CONTRIBUTION_429797
- In Indexing
- http://indexing.parliament.uk/Content/Edit/1?uri=http://data.parliament.uk/pimsdata/hansard/CONTRIBUTION_429797
- In Solr
- https://search.parliament.uk/claw/solr/?id=http://data.parliament.uk/pimsdata/hansard/CONTRIBUTION_429797